IL290458B1 - פורמולציות חיסון לצ'יקונגוניה - Google Patents

פורמולציות חיסון לצ'יקונגוניה

Info

Publication number
IL290458B1
IL290458B1 IL290458A IL29045822A IL290458B1 IL 290458 B1 IL290458 B1 IL 290458B1 IL 290458 A IL290458 A IL 290458A IL 29045822 A IL29045822 A IL 29045822A IL 290458 B1 IL290458 B1 IL 290458B1
Authority
IL
Israel
Prior art keywords
chikv
seq
virus
formulation
concentration
Prior art date
Application number
IL290458A
Other languages
English (en)
Other versions
IL290458B2 (he
IL290458A (he
Original Assignee
Valneva Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valneva Se filed Critical Valneva Se
Publication of IL290458A publication Critical patent/IL290458A/he
Publication of IL290458B1 publication Critical patent/IL290458B1/he
Publication of IL290458B2 publication Critical patent/IL290458B2/he

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL290458A 2019-08-09 2020-08-10 פורמולציות חיסון לצ'יקונגוניה IL290458B2 (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19190999 2019-08-09
PCT/EP2020/072435 WO2021028406A1 (en) 2019-08-09 2020-08-10 Chikungunya vaccine formulations

Publications (3)

Publication Number Publication Date
IL290458A IL290458A (he) 2022-04-01
IL290458B1 true IL290458B1 (he) 2025-02-01
IL290458B2 IL290458B2 (he) 2025-06-01

Family

ID=67587625

Family Applications (1)

Application Number Title Priority Date Filing Date
IL290458A IL290458B2 (he) 2019-08-09 2020-08-10 פורמולציות חיסון לצ'יקונגוניה

Country Status (11)

Country Link
US (1) US20220288185A1 (he)
EP (1) EP4010015A1 (he)
KR (1) KR20220045154A (he)
AU (1) AU2020327602A1 (he)
BR (1) BR112022002082A2 (he)
CA (1) CA3149919A1 (he)
IL (1) IL290458B2 (he)
MX (1) MX2022001430A (he)
PH (1) PH12021553186A1 (he)
WO (1) WO2021028406A1 (he)
ZA (1) ZA202202574B (he)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998013065A1 (en) * 1996-09-26 1998-04-02 Merck & Co., Inc. Rotavirus vaccine formulations
US20170014502A1 (en) * 2015-07-16 2017-01-19 Bharat Biotech International Limited Vaccine compositions
WO2017172643A1 (en) * 2016-03-31 2017-10-05 Takeda Vaccines, Inc. Compositions and methods for stabilizing alphaviruses with improved formulations
WO2019057793A1 (en) * 2017-09-21 2019-03-28 Valneva Se PROCESS FOR THE PRODUCTION OF PHARMACEUTICAL COMPOSITIONS COMPRISING THE IMMUNOGENIC VIRUS OF CHIKUNGUNYA CHIKV-DELTA5NSP3

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6949027B2 (ja) 2015-12-23 2021-10-20 バルネバ オーストリア ジーエムビーエイチ ジカウイルスワクチン

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998013065A1 (en) * 1996-09-26 1998-04-02 Merck & Co., Inc. Rotavirus vaccine formulations
US20170014502A1 (en) * 2015-07-16 2017-01-19 Bharat Biotech International Limited Vaccine compositions
WO2017172643A1 (en) * 2016-03-31 2017-10-05 Takeda Vaccines, Inc. Compositions and methods for stabilizing alphaviruses with improved formulations
WO2019057793A1 (en) * 2017-09-21 2019-03-28 Valneva Se PROCESS FOR THE PRODUCTION OF PHARMACEUTICAL COMPOSITIONS COMPRISING THE IMMUNOGENIC VIRUS OF CHIKUNGUNYA CHIKV-DELTA5NSP3

Also Published As

Publication number Publication date
EP4010015A1 (en) 2022-06-15
AU2020327602A1 (en) 2022-01-27
CA3149919A1 (en) 2021-02-18
US20220288185A1 (en) 2022-09-15
KR20220045154A (ko) 2022-04-12
IL290458B2 (he) 2025-06-01
WO2021028406A1 (en) 2021-02-18
PH12021553186A1 (en) 2022-12-12
MX2022001430A (es) 2022-02-22
BR112022002082A2 (pt) 2022-04-12
ZA202202574B (en) 2023-07-26
IL290458A (he) 2022-04-01

Similar Documents

Publication Publication Date Title
Kaur et al. COVID-19 Vaccine: A comprehensive status report
ES2908304T3 (es) Dosis unitaria de vacuna contra el dengue y administración de la misma
AU2013295014B2 (en) Vaccine compositions
TW202144570A (zh) 去最佳化(DEOPTIMIZED)SARS-CoV-2及其方法及用途
JP6968070B2 (ja) 弱毒四価デングワクチンを調製するプロセス
US10849943B2 (en) Vaccine compositions comprising an attenuated mutant Zika virus
CN105473603B (zh) 用于登革病毒疫苗的方法与组合物
EP3193922B1 (en) Vaccine
US9975923B2 (en) Methods and compositions for norovirus blockade epitopes
US20210401983A1 (en) Arthrogenic alphavirus vaccine
US20220313810A1 (en) Single shot chikungunya virus vaccine
US20190177373A1 (en) Genomic sequences encoding for an attenuated mutant zika virus
US20220288185A1 (en) Chikungunya vaccine formulations
WO2014083194A1 (en) Methods for inducing antibodies
Vainionpää COVID-19 vaccination
WO2023250055A1 (en) Immunogenic compositions for herpes simplex virus proteins
WO2020229581A1 (en) Methods for inducing a safe immune response against polio virus
CN103182081A (zh) 一种人用狂犬疫苗的制备